Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Millions wrongly told they're allergic to penicillin? study tests a fix.

NCT ID NCT03581604

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a standard allergy work-up can accurately identify people who were incorrectly labeled as allergic to penicillin. 155 adults with a suspected penicillin allergy went through testing, including a drug challenge to confirm if they were truly allergic. The goal was to safely 'de-label' those who are not actually allergic, which could improve antibiotic choices and help fight antibiotic resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Allergy work-up (diagnostic test)
What this could lead to
If successful, this could help many people who were told they are allergic to penicillin find out they are not, allowing safer and more effective antibiotic treatment.
What could go wrong
This is a small, completed study with 155 participants, so results may not apply to everyone. The allergy work-up may not catch all true allergies, and some people could still have a reaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

155 people

The number who actually took part.

Started

Sep 2017

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients who are referred to the department of Pulmonary medicine with clinical history suspected of having penicillin allergy. * The control group will be healthy adult volunteers with no history of any personal or family history of drug allergy, atopy, inflammatory or autoimmune diseases. Exclusion Criteria: * Systemic reactions such as DRESS, any internal organ involvement * Clinical history of Type II-III hypersensitivity reaction * Severe Type IV hypersensitivity reaction such as Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, vasculitis, acute generalized exanthematous pustulosis * Chronic idiopathic urticaria on antihistamine maintenance treatment/anti-IgE treatment * Medication which can affect the test outcome * Active signs of an underlying disease such as uncontrolled asthma * Cardiac disease with increased risk of serious anaphylaxis * Pregnancy/Breastfeeding * Reaction within the last 4-6 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergy drug are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Oslo University Hospital, Dpt of Pulmonary Diseases, Ullevål

    Oslo, Postbox 4950 Nydalen, 0424, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.